Navigation Links
Somanetics Corporation to Release Third Quarter 2009 Financial Results and Host Conference Call September 17, 2009
Date:9/3/2009

TROY, Mich., Sept. 3 /PRNewswire-FirstCall/ -- Somanetics Corporation (Nasdaq: SMTS) will release its financial results for the third quarter ended August 31, 2009 before the opening of the market on Thursday, September 17, 2009. In conjunction with releasing its financial results, the Company will host a conference call that will be webcast live at 10:00 a.m. (ET) the same day.

On the conference call, Bruce Barrett, Somanetics' president and chief executive officer, and Bill Iacona, chief financial officer, will review Somanetics' financial results.

To listen to the webcast, visit the Presentations & Webcasts page in the Investor Relations section of Somanetics' website at www.somanetics.com prior to the event's broadcast and click on the "Q3 2009 Somanetics Corporation Earnings Conference Call" link. Interested parties unable to listen to the live call may access the archived version of the call in the Investor Relations section of Somanetics' website for at least one year after the call.

About Somanetics

Somanetics Corporation (Nasdaq: SMTS) develops, manufactures and markets the INVOS(R) Cerebral/Somatic Oximeter which noninvasively provides accurate, real-time blood oxygen measurements in patients greater than 2.5 kilograms, and trend monitoring of this parameter for individuals of any weight. The INVOS System is the only commercially-available cerebral/somatic oximeter proven to improve outcomes. Surgeons, anesthesiologists and other medical professionals can use data provided by the INVOS System, in conjunction with other available data, to identify oxygen imbalances in brain or other body tissue beneath the sensor and take necessary corrective action, potentially improving patient outcomes and reducing the costs of care. The INVOS System is the clinical reference standard in cerebral/somatic oximetry, with an 11-year market track record, more than 700 clinical references and implementation at more than 700 U.S. hospitals. Somanetics also develops, manufactures and markets the Vital Sync(TM) System, a device that integrates data from bedside devices into a single system for enhanced patient assessment and decision making, data management and data storage. Somanetics supports its customers through a direct U.S. sales force and clinical education team. Covidien markets INVOS System products in Europe, Canada, the Middle East and Africa and Edwards Lifesciences represents INVOS System products in Japan. For more information visit www.somanetics.com.


'/>"/>
SOURCE Somanetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Somanetics Corporation to Present at Cowen & Company 28th Annual Health Care Conference
2. United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
3. ChemBridge Corporation and Collaborative Drug Discovery Announce Strategic Collaboration to Provide Diverse Chemical Libraries Together With Researchers Own Private Data
4. Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber
5. Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
6. Massachusetts Technology Corporation Named to Inc. 5000 List of Fastest Growing Private Companies
7. Microfluidics International Corporation Announces Second Quarter 2009 Financial Results
8. Centage Corporation Announces Planning Maestro Business Performance Management Software for Mid-Market Enterprises
9. Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast
10. Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009
11. CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology:
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):